183 related articles for article (PubMed ID: 28622037)
1. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
[TBL] [Abstract][Full Text] [Related]
2. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer.
Yi H; Ye T; Ge M; Yang M; Zhang L; Jin S; Ye X; Long B; Li L
Oncol Rep; 2018 Feb; 39(2):711-720. PubMed ID: 29207150
[TBL] [Abstract][Full Text] [Related]
4. pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
Yarchoan M; Ma C; Troxel AB; Stopenski SJ; Tang W; Cohen AB; Pappas-Paxinos M; Johnson BA; Chen EY; Feldman MD; Brose MS
Horm Cancer; 2016 Jun; 7(3):188-95. PubMed ID: 26994002
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression.
Zhang CZ; Wang XD; Wang HW; Cai Y; Chao LQ
J BUON; 2015; 20(1):218-22. PubMed ID: 25778319
[TBL] [Abstract][Full Text] [Related]
6. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
7. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Roulin D; Waselle L; Dormond-Meuwly A; Dufour M; Demartines N; Dormond O
Mol Cancer; 2011 Jul; 10():90. PubMed ID: 21791089
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
9. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways.
Zhang J; Yu J; Xie R; Chen W; Lv Y
Nat Prod Res; 2016 Aug; 30(16):1858-61. PubMed ID: 26299635
[TBL] [Abstract][Full Text] [Related]
12. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
14. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
15. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
16. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
[TBL] [Abstract][Full Text] [Related]
17. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
18. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma.
Chen L; Wang L; Han Z; Qin P; Niu G; Du J
Tohoku J Exp Med; 2024 Mar; 262(3):173-180. PubMed ID: 38123304
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
20. The discovery and development of sorafenib for the treatment of thyroid cancer.
White PT; Cohen MS
Expert Opin Drug Discov; 2015 Apr; 10(4):427-39. PubMed ID: 25662396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]